UBE2T and gastric cancer: (31) identified a novel UBE2T inhibitor, M435-1279, and showed that M435-1279 inhibits overactivation of the Wnt/β-catenin signaling pathway by blocking UBE2T-mediated RACK1 degradation, thereby inhibiting gastric cancer progression and reducing cytotoxicity.